These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11326675

  • 1. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 2. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 4. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Jun; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 5. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
    Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.
    Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
    [Abstract] [Full Text] [Related]

  • 6. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
    Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, Pode D.
    Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
    [Abstract] [Full Text] [Related]

  • 7. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Aug; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 8. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 9. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999 Apr; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 10. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003 Apr; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 11. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E.
    Cancer Detect Prev; 2000 Apr; 24(6):531-5. PubMed ID: 11198266
    [Abstract] [Full Text] [Related]

  • 12. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.
    Tumour Biol; 2001 Apr; 22(5):282-5. PubMed ID: 11553857
    [Abstract] [Full Text] [Related]

  • 13. Tumor M2-PK levels in haematological malignancies.
    Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H.
    Anticancer Res; 2003 Apr; 23(2A):1135-8. PubMed ID: 12820361
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 15. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB.
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [Abstract] [Full Text] [Related]

  • 16. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
    Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.
    Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
    [Abstract] [Full Text] [Related]

  • 17. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K.
    Anticancer Res; 2000 Nov; 20(6D):5077-82. PubMed ID: 11326672
    [Abstract] [Full Text] [Related]

  • 18. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Nov; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 19. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG, Zhang N.
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.